Skip to main content
Erschienen in: Endocrine 1/2017

07.07.2016 | Endocrine Trials

Comparative study between the effects of replacement therapy with liquid and tablet formulations of levothyroxine on mood states, self-perceived psychological well-being and thyroid hormone profile in recently thyroidectomized patients

verfasst von: Celestino Pio Lombardi, Raffaella Bocale, Angelina Barini, Antonella Barini, Annamaria D’Amore, Mauro Boscherini, Rocco Bellantone

Erschienen in: Endocrine | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Following thyroid surgery, levothyroxine therapy is used to replace deficient thyroid hormones and prevent postoperative thyroid hypofunction. We compared the effects of replacement therapy with either liquid or tablet formulation of levothyroxine on mood states, self-perceived mental well-being and thyroid hormone profile in recently thyroidectomized patients. Profile of mood states, General Heath Questionnaire 12-items and thyroid hormone profile were assessed in recently (5–7 days) thyroidectomized patients at baseline and 2 months after randomization to replacement therapy with either liquid (n = 77) or tablet (n = 78) formulation of levothyroxine. After 2 months under levothyroxine replacement treatment, significant improvements of Positive Affect Scale (p < 0.001) and Negative Affect Scale (p < 0.001) of Profile of mood states, as well as of General Heath Questionnaire 12-items (p < 0.001) were observed in the study population. However, there were greater variations observed in patients assigned to liquid levothyroxine formulation in comparison to those who were assigned to levothyroxine in the form of tablet (time × treatment interaction: Positive Affect Scale of Profile of mood states, p = 0.030; Negative Affect Scale of Profile of mood states, p < 0.0001; General Heath Questionnaire 12-items, p = 0.003). As expected, circulating TSH levels significantly decreased (p <0.001) while FT3 and FT4 levels significantly increased (p < 0.0001 for both) under levothyroxine replacement therapy. These changes were significantly greater in patients treated with liquid levothyroxine formulation (time × treatment interaction: TSH, p = 0.011; FT3, p = 0.016; FT4, p = 0.028). Our data indicate a greater efficacy of liquid formulation of levothyroxine in ameliorating mood states and self-perception of mental well-being and thyroid hormone profile after 2 months of replacement therapy in recently thyroidectomized patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat R. Bellantone, C.P. Lombardi, M. Bossola, M. Boscherini, C. De Crea, P. Alesina, E. Traini, P. Princi, M. Raffaelli, Total thyroidectomy for management of benign thyroid disease: review of 526 cases. World J. Surg. 26(12), 1468–1471 (2002)CrossRefPubMed R. Bellantone, C.P. Lombardi, M. Bossola, M. Boscherini, C. De Crea, P. Alesina, E. Traini, P. Princi, M. Raffaelli, Total thyroidectomy for management of benign thyroid disease: review of 526 cases. World J. Surg. 26(12), 1468–1471 (2002)CrossRefPubMed
2.
Zurück zum Zitat G. Agarwal, V. Aggarwal, Is total thyroidectomy the surgical procedure of choice for benign multinodular goiter? An evidence-based review. World J. Surg. 32(7), 1313–1324 (2008)CrossRefPubMed G. Agarwal, V. Aggarwal, Is total thyroidectomy the surgical procedure of choice for benign multinodular goiter? An evidence-based review. World J. Surg. 32(7), 1313–1324 (2008)CrossRefPubMed
3.
Zurück zum Zitat E.I. Efremidou, M.S. Papageorgiou, N. Liratzopoulos, K.J. Manolas, The efficacy and safety of total thyroidectomy in the management of benign thyroid disease: a review of 932 cases. Can. J. Surg. 52(1), 39–44 (2009)PubMedPubMedCentral E.I. Efremidou, M.S. Papageorgiou, N. Liratzopoulos, K.J. Manolas, The efficacy and safety of total thyroidectomy in the management of benign thyroid disease: a review of 932 cases. Can. J. Surg. 52(1), 39–44 (2009)PubMedPubMedCentral
4.
Zurück zum Zitat N. Verhaert, V. Vander Poorten, P. Delaere, M. Bex, F. Debruyne, Levothyroxine replacement therapy after thyroid surgery. B-ENT. 2(3), 129–133 (2006)PubMed N. Verhaert, V. Vander Poorten, P. Delaere, M. Bex, F. Debruyne, Levothyroxine replacement therapy after thyroid surgery. B-ENT. 2(3), 129–133 (2006)PubMed
5.
Zurück zum Zitat W.M. Wiersinga, Thyroid hormone replacement therapy. Horm. Res. 56(Suppl 1), 74–81 (2001)PubMed W.M. Wiersinga, Thyroid hormone replacement therapy. Horm. Res. 56(Suppl 1), 74–81 (2001)PubMed
6.
Zurück zum Zitat A. Schäffler, Hormone replacement after thyroid and parathyroid surgery. Dtsch. Arztebl. Int. 107(47), 827–834 (2010)PubMedPubMedCentral A. Schäffler, Hormone replacement after thyroid and parathyroid surgery. Dtsch. Arztebl. Int. 107(47), 827–834 (2010)PubMedPubMedCentral
8.
Zurück zum Zitat J. Jonklaas, A.C. Bianco, A.J. Bauer, K.D. Burman, A.R. Cappola, F.S. Celi, D.S. Cooper, B.W. Kim, R.P. Peeters, M.S. Rosenthal, A.M. Sawka, American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid 24(12), 1670–1751 (2014)CrossRefPubMedPubMedCentral J. Jonklaas, A.C. Bianco, A.J. Bauer, K.D. Burman, A.R. Cappola, F.S. Celi, D.S. Cooper, B.W. Kim, R.P. Peeters, M.S. Rosenthal, A.M. Sawka, American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid 24(12), 1670–1751 (2014)CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat P. Saravanan, W.F. Chau, N. Roberts, K. Vedhara, R. Greenwood, C.M. Dayan, Psychological well-being in patients on ‘adequate’ doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin. Endocrinol. 57(5), 577–585 (2002)CrossRef P. Saravanan, W.F. Chau, N. Roberts, K. Vedhara, R. Greenwood, C.M. Dayan, Psychological well-being in patients on ‘adequate’ doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin. Endocrinol. 57(5), 577–585 (2002)CrossRef
10.
11.
Zurück zum Zitat P. Eadala, J.P. Waud, S.B. Matthews, J.T. Green, A.K. Campbell, Quantifying the ‘hidden’ lactose in drugs used for the treatment of gastrointestinal conditions. Aliment. Pharmacol. Ther. 29, 677–687 (2009)CrossRefPubMed P. Eadala, J.P. Waud, S.B. Matthews, J.T. Green, A.K. Campbell, Quantifying the ‘hidden’ lactose in drugs used for the treatment of gastrointestinal conditions. Aliment. Pharmacol. Ther. 29, 677–687 (2009)CrossRefPubMed
12.
Zurück zum Zitat M. Centanni, L. Gargano, G. Canettieri G, N. Viceconti, A. Franchi, G. Delle Fave, B. Annibale, Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N. Engl. J. Med. 354, 1787–1795 (2006)CrossRefPubMed M. Centanni, L. Gargano, G. Canettieri G, N. Viceconti, A. Franchi, G. Delle Fave, B. Annibale, Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N. Engl. J. Med. 354, 1787–1795 (2006)CrossRefPubMed
13.
Zurück zum Zitat C. Virili, G. Bassotti, M.G. Santaguida, R. Iuorio, S.C. Del Duca, V. Mercuri, A. Picarelli, P. Gargiulo, L. Gargano, M. Centanni, Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J. Clin. Endocrinol. Metab. 97, E419–E422 (2012)CrossRefPubMed C. Virili, G. Bassotti, M.G. Santaguida, R. Iuorio, S.C. Del Duca, V. Mercuri, A. Picarelli, P. Gargiulo, L. Gargano, M. Centanni, Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J. Clin. Endocrinol. Metab. 97, E419–E422 (2012)CrossRefPubMed
14.
Zurück zum Zitat M. Asik, F. Gunes, E. Binnetoglu, M. Eroglu, N. Bozkurt, H. Sen, E. Akbal, C. Bakar, Y. Beyazit, K. Ukinc, Decrease in TSH levels after lactose restriction in Hashimoto’s thyroiditis patients with lactose intolerance. Endocrine 46(2), 279–284 (2014)CrossRefPubMed M. Asik, F. Gunes, E. Binnetoglu, M. Eroglu, N. Bozkurt, H. Sen, E. Akbal, C. Bakar, Y. Beyazit, K. Ukinc, Decrease in TSH levels after lactose restriction in Hashimoto’s thyroiditis patients with lactose intolerance. Endocrine 46(2), 279–284 (2014)CrossRefPubMed
15.
Zurück zum Zitat L. Liwampo, J.M. Hershman, Conditions and drugs interfering with thyroxine absorption. Best Pract. Res. Clin. Endocrinol. Metab. 23, 781–792 (2009)CrossRef L. Liwampo, J.M. Hershman, Conditions and drugs interfering with thyroxine absorption. Best Pract. Res. Clin. Endocrinol. Metab. 23, 781–792 (2009)CrossRef
16.
Zurück zum Zitat R. Padwal, D. Brocks, A.M. Sharma, A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes. Rev. 11, 41–50 (2010)CrossRefPubMed R. Padwal, D. Brocks, A.M. Sharma, A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes. Rev. 11, 41–50 (2010)CrossRefPubMed
17.
Zurück zum Zitat J.J. Lilja, K. Laitinen, P.J. Neuvonen, Effects of grapefruit juice on the absorption of levothyroxine. Br. J. Clin. Pharmacol. 60, 337–341 (2005)CrossRefPubMedPubMedCentral J.J. Lilja, K. Laitinen, P.J. Neuvonen, Effects of grapefruit juice on the absorption of levothyroxine. Br. J. Clin. Pharmacol. 60, 337–341 (2005)CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat S. Benvenga, L. Bartolone, M.A. Pappalardo, A. Russo, D. Lapa, G. Giorgianni, G. Saraceno, F. Trimarchi, Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid 18, 293–301 (2008)CrossRefPubMed S. Benvenga, L. Bartolone, M.A. Pappalardo, A. Russo, D. Lapa, G. Giorgianni, G. Saraceno, F. Trimarchi, Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid 18, 293–301 (2008)CrossRefPubMed
19.
Zurück zum Zitat S. Benvenga, L. Bartolone, S. Squadrito, F. Lo Giudice, F. Trimarchi, Delayed intestinal absorption of levothyroxine. Thyroid 5, 249–253 (1995)CrossRefPubMed S. Benvenga, L. Bartolone, S. Squadrito, F. Lo Giudice, F. Trimarchi, Delayed intestinal absorption of levothyroxine. Thyroid 5, 249–253 (1995)CrossRefPubMed
20.
Zurück zum Zitat T.G. Bach-Huynh, B. Nayak, J. Loh, S. Soldin, J. Jonklaas, Timing of levothyroxine administration affects serum thyrotropin concentration. J. Clin. Endocrinol. Metab. 94(10), 3905–3912 (2009)CrossRefPubMedPubMedCentral T.G. Bach-Huynh, B. Nayak, J. Loh, S. Soldin, J. Jonklaas, Timing of levothyroxine administration affects serum thyrotropin concentration. J. Clin. Endocrinol. Metab. 94(10), 3905–3912 (2009)CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat R. Vita, P. Fallahi, A. Antonelli, S. Benvenga, The administration of L-thyroxine as soft gel capsule or liquid solution. Expert Opin. Drug. Deliv. 11(7), 1103–1111 (2014)CrossRefPubMed R. Vita, P. Fallahi, A. Antonelli, S. Benvenga, The administration of L-thyroxine as soft gel capsule or liquid solution. Expert Opin. Drug. Deliv. 11(7), 1103–1111 (2014)CrossRefPubMed
22.
Zurück zum Zitat M. Centanni, Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches. Endocrine 43(1), 8–9 (2013)CrossRefPubMed M. Centanni, Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches. Endocrine 43(1), 8–9 (2013)CrossRefPubMed
23.
Zurück zum Zitat R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga., A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 43(1), 154–160 (2013)CrossRefPubMed R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga., A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 43(1), 154–160 (2013)CrossRefPubMed
24.
Zurück zum Zitat S. Morelli, G. Reboldi, S. Moretti, E. Menicali, N. Avenia, E. Puxeddu, Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation. Endocrine (2015). doi:10.1007/s12020-015-0788-2 S. Morelli, G. Reboldi, S. Moretti, E. Menicali, N. Avenia, E. Puxeddu, Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation. Endocrine (2015). doi:10.​1007/​s12020-015-0788-2
25.
Zurück zum Zitat P. Fallahi, S.M. Ferrari, A. Antonelli., Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study. Endocrine (2015). doi:10.1007/s12020-015-0836-y P. Fallahi, S.M. Ferrari, A. Antonelli., Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study. Endocrine (2015). doi:10.​1007/​s12020-015-0836-y
26.
Zurück zum Zitat P. Fallahi, S.M. Ferrari, I. Ruffilli, A. Antonelli, Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series. B.M.C, Gastroenterol 16(1), 22 (2016). doi:10.1186/s12876-016-0439-y CrossRef P. Fallahi, S.M. Ferrari, I. Ruffilli, A. Antonelli, Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series. B.M.C, Gastroenterol 16(1), 22 (2016). doi:10.​1186/​s12876-016-0439-y CrossRef
27.
Zurück zum Zitat D.M. McNair, M. Lorr, L.F. Droppleman. EITS manual for the Profile of Mood States. (Educational and Industrial Testing Service, San Diego, CA, 1971) D.M. McNair, M. Lorr, L.F. Droppleman. EITS manual for the Profile of Mood States. (Educational and Industrial Testing Service, San Diego, CA, 1971)
28.
Zurück zum Zitat M. Farnè, A. Sebellico, D. Gnugnoli, A. Corallo. Profile of Mood States, Manuale di istruzioni. Giunti OS, Florence (1991) M. Farnè, A. Sebellico, D. Gnugnoli, A. Corallo. Profile of Mood States, Manuale di istruzioni. Giunti OS, Florence (1991)
29.
Zurück zum Zitat F.-X. Lesage, S. Martens-Resende, F. Deschamps F, S. Berjot, Validation of the General Health Questionnaire (GHQ-12) adapted to a work-related context. Open. J. Prev. Med. 1, 44–8 (2011) F.-X. Lesage, S. Martens-Resende, F. Deschamps F, S. Berjot, Validation of the General Health Questionnaire (GHQ-12) adapted to a work-related context. Open. J. Prev. Med. 1, 44–8 (2011)
30.
Zurück zum Zitat Goldberg D, Williams P. A user’s guide to the general health questionnaire. NFER-Nelson (1991) Goldberg D, Williams P. A user’s guide to the general health questionnaire. NFER-Nelson (1991)
31.
Zurück zum Zitat M. Piccinelli, G. Bisoffi, M.G. Bon, L. Cunico, M. Tansella, Validity and test-retest reliability of the Italian version of the 12-item GHQ in general practice: a comparison between three scoring methods. Compr. Psychiatry 34, 198–205 (1993)CrossRefPubMed M. Piccinelli, G. Bisoffi, M.G. Bon, L. Cunico, M. Tansella, Validity and test-retest reliability of the Italian version of the 12-item GHQ in general practice: a comparison between three scoring methods. Compr. Psychiatry 34, 198–205 (1993)CrossRefPubMed
32.
Zurück zum Zitat H. Zulewski, B. Müller, P. Exer, A.R. Miserez, J.J. Staub, Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J. Clin. Endocrinol. Metab. 82(3), 771–776 (1997)PubMed H. Zulewski, B. Müller, P. Exer, A.R. Miserez, J.J. Staub, Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J. Clin. Endocrinol. Metab. 82(3), 771–776 (1997)PubMed
33.
Zurück zum Zitat S. Tagay, S. Herpertz, M. Langkafel, Y. Erim, L. Freudenberg, N. Schöpper, A. Bockisch, W. Senf, R. Görges, R. Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur. J. Endocrinol. 153, 755–763 (2005)CrossRefPubMed S. Tagay, S. Herpertz, M. Langkafel, Y. Erim, L. Freudenberg, N. Schöpper, A. Bockisch, W. Senf, R. Görges, R. Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur. J. Endocrinol. 153, 755–763 (2005)CrossRefPubMed
34.
Zurück zum Zitat J.I. Botella-Carretero, J.M. Galán, C. Caballero, J. Sancho, H.F. Escobar-Morreale, Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocr. Relat. Cancer 10, 601–610 (2003)CrossRefPubMed J.I. Botella-Carretero, J.M. Galán, C. Caballero, J. Sancho, H.F. Escobar-Morreale, Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocr. Relat. Cancer 10, 601–610 (2003)CrossRefPubMed
35.
Zurück zum Zitat C.F. Eustatia-Rutten, E.P. Corssmit, A.M. Pereira, M. Frölich, J.J. Bax, J.A. Romijn, J.W. Smit, Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. Clin. Endocrinol. 64, 284–291 (2006)CrossRef C.F. Eustatia-Rutten, E.P. Corssmit, A.M. Pereira, M. Frölich, J.J. Bax, J.A. Romijn, J.W. Smit, Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. Clin. Endocrinol. 64, 284–291 (2006)CrossRef
36.
Zurück zum Zitat M. Sait Gönen, G. Kisakol, A. Savas Cilli, O. Dikbas, K. Gungor, A. Inal, A. Kaya, Assessment of anxiety in subclinical thyroid disorders. Endocr. J. 51, 311–315 (2004)CrossRefPubMed M. Sait Gönen, G. Kisakol, A. Savas Cilli, O. Dikbas, K. Gungor, A. Inal, A. Kaya, Assessment of anxiety in subclinical thyroid disorders. Endocr. J. 51, 311–315 (2004)CrossRefPubMed
37.
Zurück zum Zitat S. Gulseren, L. Gulseren, Z. Hekimsoy, P. Cetinay, C. Ozen, B. Tokatlioglu, Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction. Arch. Med. Res. 37, 133–139 (2006)CrossRefPubMed S. Gulseren, L. Gulseren, Z. Hekimsoy, P. Cetinay, C. Ozen, B. Tokatlioglu, Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction. Arch. Med. Res. 37, 133–139 (2006)CrossRefPubMed
38.
Zurück zum Zitat R.T. de Jongh, P. Lips, N.M. van Schoor, K.J. Rijs, D.J. Deeg, H.C. Comijs, M.H. Kramer, J.P. Vandenbroucke, O.M. Dekkers, Endogenous subclinical thyroid disorders, physical and cognitive function, depression, and mortality in older individuals. Eur. J. Endocrinol. 165, 545–554 (2011)CrossRefPubMed R.T. de Jongh, P. Lips, N.M. van Schoor, K.J. Rijs, D.J. Deeg, H.C. Comijs, M.H. Kramer, J.P. Vandenbroucke, O.M. Dekkers, Endogenous subclinical thyroid disorders, physical and cognitive function, depression, and mortality in older individuals. Eur. J. Endocrinol. 165, 545–554 (2011)CrossRefPubMed
39.
Zurück zum Zitat A. Engum, T. Bjøro, A. Mykletun, A.A. Dahl, An association between depression, anxiety and thyroid function—a clinical fact or an artefact? Acta Psychiatr. Scand. 106, 27–34 (2002)CrossRefPubMed A. Engum, T. Bjøro, A. Mykletun, A.A. Dahl, An association between depression, anxiety and thyroid function—a clinical fact or an artefact? Acta Psychiatr. Scand. 106, 27–34 (2002)CrossRefPubMed
40.
Zurück zum Zitat G.P. Bianchi, V. Zaccheroni, E. Solaroli, F. Vescini, R. Cerutti, M. Zoli, G. Marchesini, Health-related quality of life in patients with thyroid disorders. Qual. Life Res. 13(1), 45–54 (2004)CrossRefPubMed G.P. Bianchi, V. Zaccheroni, E. Solaroli, F. Vescini, R. Cerutti, M. Zoli, G. Marchesini, Health-related quality of life in patients with thyroid disorders. Qual. Life Res. 13(1), 45–54 (2004)CrossRefPubMed
41.
Zurück zum Zitat R. Watrowski, A. Rohde, M. Maciejewska-Jeske, B. Meczekalski, Hormonal and psychosocial correlates of psychological well-being and negative affectivity in young gynecological-endocrinological patients. Gynecol. Endocrinol. 32(1), 21–24 (2016)CrossRefPubMed R. Watrowski, A. Rohde, M. Maciejewska-Jeske, B. Meczekalski, Hormonal and psychosocial correlates of psychological well-being and negative affectivity in young gynecological-endocrinological patients. Gynecol. Endocrinol. 32(1), 21–24 (2016)CrossRefPubMed
42.
Zurück zum Zitat M. Valizadeh, M.R. Seyyed-Majidi, H. Hajibeigloo, S. Momtazi, N. Musavinasab, M.R. Hayatbakhsh, Efficacy of combined levothyroxine and liothyronine as compared with levothyroxine monotherapy in primary hypothyroidism: a randomized controlled trial. Endocr. Res. 34(3), 80–89 (2009)CrossRefPubMed M. Valizadeh, M.R. Seyyed-Majidi, H. Hajibeigloo, S. Momtazi, N. Musavinasab, M.R. Hayatbakhsh, Efficacy of combined levothyroxine and liothyronine as compared with levothyroxine monotherapy in primary hypothyroidism: a randomized controlled trial. Endocr. Res. 34(3), 80–89 (2009)CrossRefPubMed
43.
Zurück zum Zitat C.D. Moulton, J.C. Pickup, K. Ismail., The link between depression and diabetes: the search for shared mechanisms. Lancet Diabetes Endocrinol 3(6), 461–471 (2015)CrossRefPubMed C.D. Moulton, J.C. Pickup, K. Ismail., The link between depression and diabetes: the search for shared mechanisms. Lancet Diabetes Endocrinol 3(6), 461–471 (2015)CrossRefPubMed
44.
Zurück zum Zitat I. Kowalska, J. Borawski, A. Nikołajuk, T. Budlewski, E. Otziomek, M. Górska, M. Strączkowski, Insulin sensitivity, plasma adiponectin and sICAM-1 concentrations in patients with subclinical hypothyroidism: response to levothyroxine therapy. Endocrine 40(1), 95–101 (2011)CrossRefPubMed I. Kowalska, J. Borawski, A. Nikołajuk, T. Budlewski, E. Otziomek, M. Górska, M. Strączkowski, Insulin sensitivity, plasma adiponectin and sICAM-1 concentrations in patients with subclinical hypothyroidism: response to levothyroxine therapy. Endocrine 40(1), 95–101 (2011)CrossRefPubMed
45.
Zurück zum Zitat O. Deyneli, I.N. Akpınar, O.S. Meriçliler, H. Gözü, M.E. Yıldız, N.S. Akalın, Effects of levothyroxine treatment on insulin sensitivity, endothelial function and risk factors of atherosclerosis in hypothyroid women. Ann. Endocrinol. 75(4), 220–226 (2014)CrossRef O. Deyneli, I.N. Akpınar, O.S. Meriçliler, H. Gözü, M.E. Yıldız, N.S. Akalın, Effects of levothyroxine treatment on insulin sensitivity, endothelial function and risk factors of atherosclerosis in hypothyroid women. Ann. Endocrinol. 75(4), 220–226 (2014)CrossRef
46.
Zurück zum Zitat C.S. Yue, C. Scarsi, M.P. Ducharme., Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung 62, 631–636 (2012)CrossRefPubMed C.S. Yue, C. Scarsi, M.P. Ducharme., Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung 62, 631–636 (2012)CrossRefPubMed
47.
Zurück zum Zitat C. Cappelli, I. Pirola, E. Gandossi, A. Formenti, M. Castellano, Oral liquid levothyroxine treatment at breakfast: a mistake? Eur. J. Endocrinol. 170, 95–99 (2013)CrossRefPubMed C. Cappelli, I. Pirola, E. Gandossi, A. Formenti, M. Castellano, Oral liquid levothyroxine treatment at breakfast: a mistake? Eur. J. Endocrinol. 170, 95–99 (2013)CrossRefPubMed
48.
Zurück zum Zitat A. Bernareggi, E. Grata, M.T. Pinorini, A. Conti, Oral liquid formulation of Levothyroxine is stable in breakfast and may improve thyroid patient compliance. Pharmaceutics 5, 621–633 (2013)CrossRefPubMedPubMedCentral A. Bernareggi, E. Grata, M.T. Pinorini, A. Conti, Oral liquid formulation of Levothyroxine is stable in breakfast and may improve thyroid patient compliance. Pharmaceutics 5, 621–633 (2013)CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat D. Brancato, A. Scorsone, G. Saura, L. Ferrara, A. Di Noto, V. Aiello, M. Fleres, V. Provenzano, Comparison of TSH Levels with liquid formulation Versus Tablet Formulations of Levothyroxine in the treatment of adult hypothyroidism. Endocr. Pract. 20(7), 657–662 (2014)CrossRefPubMed D. Brancato, A. Scorsone, G. Saura, L. Ferrara, A. Di Noto, V. Aiello, M. Fleres, V. Provenzano, Comparison of TSH Levels with liquid formulation Versus Tablet Formulations of Levothyroxine in the treatment of adult hypothyroidism. Endocr. Pract. 20(7), 657–662 (2014)CrossRefPubMed
50.
Zurück zum Zitat M. Prats Julià, Effect of treatment with levothyroxine in the lipid profile of the patients with subclinical hypothyroidism. Endocrinol. Nutr. 56(1), 13–17 (2009)CrossRefPubMed M. Prats Julià, Effect of treatment with levothyroxine in the lipid profile of the patients with subclinical hypothyroidism. Endocrinol. Nutr. 56(1), 13–17 (2009)CrossRefPubMed
51.
Zurück zum Zitat A. Iqbal, R. Jorde, Y. Figenschau, Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromsø Study. J. Intern. Med. 260(1), 53–61 (2006)CrossRefPubMed A. Iqbal, R. Jorde, Y. Figenschau, Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromsø Study. J. Intern. Med. 260(1), 53–61 (2006)CrossRefPubMed
52.
Zurück zum Zitat F. Monzani, N. Caraccio, M. Kozàkowà, A. Dardano, F. Vittone, A. Virdis, S. Taddei, C. Palombo, E. Ferrannini, Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 89(5), 2099–2106 (2004)CrossRefPubMed F. Monzani, N. Caraccio, M. Kozàkowà, A. Dardano, F. Vittone, A. Virdis, S. Taddei, C. Palombo, E. Ferrannini, Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 89(5), 2099–2106 (2004)CrossRefPubMed
53.
Zurück zum Zitat Y. Erbil, N. Ozbey, M. Giriş, A. Salmaslioğlu, S. Ozarmağan, S. Tezelman, Effects of thyroxine replacement on lipid profile and endothelial function after thyroidectomy. Br. J. Surg. 94(12), 1485–1490 (2007)CrossRefPubMed Y. Erbil, N. Ozbey, M. Giriş, A. Salmaslioğlu, S. Ozarmağan, S. Tezelman, Effects of thyroxine replacement on lipid profile and endothelial function after thyroidectomy. Br. J. Surg. 94(12), 1485–1490 (2007)CrossRefPubMed
Metadaten
Titel
Comparative study between the effects of replacement therapy with liquid and tablet formulations of levothyroxine on mood states, self-perceived psychological well-being and thyroid hormone profile in recently thyroidectomized patients
verfasst von
Celestino Pio Lombardi
Raffaella Bocale
Angelina Barini
Antonella Barini
Annamaria D’Amore
Mauro Boscherini
Rocco Bellantone
Publikationsdatum
07.07.2016
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2017
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1003-9

Weitere Artikel der Ausgabe 1/2017

Endocrine 1/2017 Zur Ausgabe

Clinical Management of Endocrine Diseases

SIADH: differential diagnosis and clinical management

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.